{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T19:15:50Z","timestamp":1782674150414,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"DOI":"10.7759\/cureus.83118","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:40:14Z","timestamp":1745836814000},"source":"Crossref","is-referenced-by-count":2,"title":["Olanzapine Versus Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Indrani","family":"Sarma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukainnya","family":"Buragohain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joonmoni","family":"Lahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyotosh","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Chetia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pakesh","family":"Baishya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibyajyoti","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao KV","year":"2012","unstructured":"Rao KV, Faso A. Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits. 2012, 5:232-40.","journal-title":"Am Health Drug Benefits"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29110650","article-title":"Olanzapine for the prevention and treatment of chemotherapy-induced nausea and vomiting: a review to identify the best way to administer the drug","volume":"29","author":"Zhang XL","year":"2022","unstructured":"Zhang XL, Ying JE. Olanzapine for the prevention and treatment of chemotherapy-induced nausea and vomiting: a review to identify the best way to administer the drug. Curr Oncol. 2022, 29:8235-43. 10.3390\/curroncol29110650","journal-title":"Curr Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2014.5.1.8","article-title":"Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting","volume":"5","author":"Brafford MV","year":"2014","unstructured":"Brafford MV, Glode A. Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol. 2014, 5:24-9. 10.6004\/jadpro.2014.5.1.8","journal-title":"J Adv Pract Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.10894","article-title":"Efficacy of olanzapine in addition to standard triplet antiemetic therapy for cisplatin-based chemotherapy: a secondary analysis of the J-FORCE randomized clinical trial","volume":"6","author":"Abe M","year":"2023","unstructured":"Abe M, Yamaguchi T, Fujita Y, et al.. Efficacy of olanzapine in addition to standard triplet antiemetic therapy for cisplatin-based chemotherapy: a secondary analysis of the J-FORCE randomized clinical trial. JAMA Netw Open. 2023, 6:e2310894. 10.1001\/jamanetworkopen.2023.10894","journal-title":"JAMA Netw Open"},{"key":"ref5","article-title":"Antiemetic neurokinin-1 receptor blockers","author":"Ibrahim MA","year":"2025","unstructured":"Ibrahim MA, Pellegrini MV, Preuss CV. Antiemetic neurokinin-1 receptor blockers. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and fosaprepitant: a 10-year review of efficacy and safety","volume":"20","author":"Aapro M","year":"2015","unstructured":"Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist. 2015, 20:450-8. 10.1634\/theoncologist.2014-0229","journal-title":"Oncologist"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial","volume":"4","author":"Wang DS","year":"2021","unstructured":"Wang DS, Hu MT, Wang ZQ, et al.. Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial. JAMA Netw Open. 2021, 4:e215250. 10.1001\/jamanetworkopen.2021.5250","journal-title":"JAMA Netw Open"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/595894","article-title":"Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting","volume":"2015","author":"Navari RM","year":"2015","unstructured":"Navari RM. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int. 2015, 2015:595894. 10.1155\/2015\/595894","journal-title":"Biomed Res Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.9591","article-title":"American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006","volume":"24","author":"Kris MG","year":"2006","unstructured":"Kris MG, Hesketh PJ, Somerfield MR, et al.. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006, 24:2932-47. 10.1200\/JCO.2006.06.9591","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective","volume":"10","author":"Vaid AK","year":"2020","unstructured":"Vaid AK, Gupta S, Doval DC, et al.. Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective. Front Oncol. 2020, 10:400. 10.3389\/fonc.2020.00400","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5954379","article-title":"A comparison of the efficacy of 5\u2009mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting","volume":"2022","author":"Liu G","year":"2022","unstructured":"Liu G, Jin Y, Jiang Y, et al.. A comparison of the efficacy of 5\u2009mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting. Int J Clin Pract. 2022, 2022:5954379. 10.1155\/2022\/5954379","journal-title":"Int J Clin Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e24078","article-title":"Efficacy, safety and cost effectiveness of reduced-dose olanzapine versus aprepitant as a part of triple-antiemetic therapy in the prevention of chemotherapy induced nausea and vomiting","volume":"1","author":"Mohammed O","year":"2022","unstructured":"Mohammed O, Thota NK. Efficacy, safety and cost effectiveness of reduced-dose olanzapine versus aprepitant as a part of triple-antiemetic therapy in the prevention of chemotherapy induced nausea and vomiting. J Clin Oncol. 2022, 1:24078. 10.1200\/JCO.2022.40.16_suppl.e24078","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.59338\/cmj.5","article-title":"Olanzapine versus aprepitant as antiemetic in highly emetogenic chemotherapy - a randomized clinical trial","volume":"27","author":"Sapkota S","year":"2023","unstructured":"Sapkota S, Pandit S, Mahaseth R. Olanzapine versus aprepitant as antiemetic in highly emetogenic chemotherapy - a randomized clinical trial. Civ Med J. 2023, 27:23-8. 10.59338\/cmj.5","journal-title":"Civ Med J"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari RM","year":"2011","unstructured":"Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011, 9:188-95.","journal-title":"J Support Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05380-6","article-title":"Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy","volume":"28","author":"Ithimakin S","year":"2020","unstructured":"Ithimakin S, Theeratrakul P, Laocharoenkiat A, et al.. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer. 2020, 28:5335-42. 10.1007\/s00520-020-05380-6","journal-title":"Support Care Cancer"},{"key":"ref16","article-title":"A comparative study of aprepitant and olanzapine in prevention of chemotherapy induced nausea and vomiting in carcinoma breast patients","volume":"14","author":"Mukesh","year":"2023","unstructured":"Mukesh, Nishitha SB, Akshay JK, Sathya. A comparative study of aprepitant and olanzapine in prevention of chemotherapy induced nausea and vomiting in carcinoma breast patients. J Cardiovasc Dis Res. 2023, 14:2122-5.","journal-title":"J Cardiovasc Dis Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3439707","article-title":"The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India","volume":"2016","author":"Babu G","year":"2016","unstructured":"Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L, et al.. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from South India. Chemother Res Pract. 2016, 2016:3439707. 10.1155\/2016\/3439707","journal-title":"Chemother Res Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3971\/j.issn.1000-8578.2017.05.009","article-title":"Aprepitant versus olanzapine for prevention of nausea and vomiting induced by multi-day chemotherapy in female lung cancer or breast cancer patients","volume":"44","author":"Shuang D","year":"2017","unstructured":"Shuang D, Wang Jun, Sheng Hu, Guoxiang L, Fengming R. Aprepitant versus olanzapine for prevention of nausea and vomiting induced by multi-day chemotherapy in female lung cancer or breast cancer patients. J Cancer Res Prevent Treat. 2017, 44:356-9. 10.3971\/j.issn.1000-8578.2017.05.009","journal-title":"J Cancer Res Prevent Treat"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05935-7","article-title":"Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature","volume":"29","author":"Chow R","year":"2021","unstructured":"Chow R, Herrstedt J, Aapro M, et al.. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021, 29:3439-59. 10.1007\/s00520-020-05935-7","journal-title":"Support Care Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.02.017","article-title":"Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"112","author":"Yoodee J","year":"2017","unstructured":"Yoodee J, Permsuwan U, Nimworapan M. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017, 112:113-25. 10.1016\/j.critrevonc.2017.02.017","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/956785","article-title":"Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy","volume":"2015","author":"Abe M","year":"2015","unstructured":"Abe M, Kasamatsu Y, Kado N, et al.. Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy. Biomed Res Int. 2015, 2015:956785. 10.1155\/2015\/956785","journal-title":"Biomed Res Int"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353995-olanzapine-versus-aprepitant-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T10:40:17Z","timestamp":1745836817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353995-olanzapine-versus-aprepitant-for-the-prevention-of-chemotherapy-induced-nausea-and-vomiting-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.83118","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}